Another Useful Test

The company's commitment to demonstrating the clinical utility of its services was also clear from the development of its Rapid BRACAnalysis test, one of Myriad's laboratory analysis options described in chapter 2. For approximately 4,000, clients could get the results of a full-sequence analysis of both BRCA genes within seven days. The company, who stated that this service had been initiated at the request of surgeons, targeted this service to clients who had already been diagnosed with...

Beyond Breast Cancer Informing Technology Policymaking

Genetic medicine is still in its early stages in the United States and Britain, and its shape has not completely stabilized. As more genetic tests are offered, their provision continues to be a subject of considerable public debate. Genetic testing for Alzheimer's Disease is now available, but it raises the same kinds of issues as BRCA testing, as the genes found are linked only to a small subset of patients who contract the disease at an early age. Related technologies are also being developed...